. . . . . . . . . . . . . . . . . . . . "a(SCHEM:\"SB-203580\") -| (p(HGNC:TNF) -> kin(p(HGNC:MAPKAPK3)))" . "p(HGNC:TNF) -> kin(p(HGNC:MAPKAPK3))" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "20131211" . "TNF? also induced in HUVEC, a marked time- and dose-dependent stimulation of SAPK2/p38 that is characterized by an increased activity of MAPKAP K2/3, a direct physiological target of SAPK2/p38 (21). Maximal stimulation was obtained after a 10-min exposure to concentrations of TNFalpha equal to or higher than 5 ng/ml (Fig. 3,A and B). The pyridinylimidazole derivative SB203580, in concentrations of 1?5 ?m, completely inhibited the TNFalpha-induced increase in SAPK2/p38 activity as reflected by the inhibition of MAPKAP K2/3 activation in cells exposed to TNFalpha (Fig. 3 C). " . . "Selventa" . . . . "2014-07-03T14:31:42.567+02:00"^^ . . .